Talicia, a novel drug for the treatment of Helicobacter pylori, achieved positive top-line results in a phase 3 study, according to a press release from RedHill Biopharma, the manufacturer.

David Graham, MD, MACG, lead investigator for the trial, said the efficacy of current H. pylori therapies are in decline due to the bacteria’s high resistance.